Elephas has closed a $55 million Series C funding round led by Venture Investors Health Fund and State of Wisconsin Investment Board (SWIB), the company announced today.

“We remain intensely focused on our mission to improve care for cancer patients,” Elephas CEO Maneesh Arora said in a statement. “Supported by world-class venture firms, we are committed to building a platform that can help guide clinicians and enhance access to life-changing immunotherapies.”

According to a release, Elephas is conducting observational clinical trials to demonstrate that a patient’s clinical response to immunotherapy is correlated to the response data obtained by the Elephas platform. 

Northpond Ventures, ARCH Ventures, Sands Capital, Moore Strategic Ventures, Tao Invest and WARF Ventures made additional investments. With this recent funding round, Elephas has raised a total of $116.5 million.

As previously reported, the company is developing an oncology imaging diagnostics platform to predict response to immunotherapy using the latest advances in metabolic imaging.